FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, namely to oncology, and can be used to treat cancer in a patient in need thereof. For this, a therapeutically effective amount of the alpha-isoform selective phosphatidylinositol 3-kinase inhibitor (I) is an orally administered to a patient in a daily dose of about 100 mg to about 450 mg for at least two five-consecutive day cycles, wherein said compound or a pharmaceutically acceptable salt thereof is not administered to the patient for a period of about 2 days to about 3 days between one five-consecutive day cycle and its subsequent five- consecutive day cycle. Also provided is a method of treating cancer if said patient has a side effect after administration of said compound of formula (I).
EFFECT: group of inventions provides treatment of cancer in a patient.
12 cl, 15 dwg, 2 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
PI-3 KINASE DOSAGE REGIME | 2013 |
|
RU2630975C2 |
COMBINATION OF PI3 KINASE INHIBITOR WITH PACLITAXEL FOR USE IN TREATMENT OR PREVENTION OF HEAD AND NECK CANCER | 2014 |
|
RU2672555C2 |
USE OF 2-CARBOXAMIDE-CYCLOAMINO UREA DERIVATIVES IN TREATMENT OF EGFR-DEPENDENT DISEASES OR DISEASES WITH ACQUIRED RESISTANCE TO AGENTS TARGETED AT EGFR-FAMILY MEMBERS | 2011 |
|
RU2589695C2 |
2-CARBOXAMIDE CYCLOAMINO UREA DERIVATIVES IN COMBINATION WITH HSP90 INHIBITORS FOR TREATING PROLIFERATIVE DISEASES | 2012 |
|
RU2624493C2 |
THERAPEUTIC COMBINATIONS CONTAINING RAF INHIBITOR AND ERK INHIBITOR | 2017 |
|
RU2774612C2 |
COMBINED THERAPY BY USING PENTAFLUOROBENZENE SULFONAMIDES | 2000 |
|
RU2268054C2 |
METHOD OF TREATMENT BY APPLICATION OF COMBINED THERAPY | 2010 |
|
RU2543348C2 |
COMPOSITION COMPRISING N-{5-[4-(4-METHYLPIPERAZINOMETHYL)BENZOYLAMIDO]-2-METHYLPHENYL}-4-(3-PYRILYL)-2-PYRIDINEAMINE AND CHEMOTHERAPEURIC AGENT | 2002 |
|
RU2318517C2 |
PHARMACEUTICAL COMBINATIONS OF CDK4/6 INHIBITOR AND B-Raf INHIBITOR | 2013 |
|
RU2685250C2 |
COMBINATIONS CONTAINING TRANSDUCTION SIGNAL INHIBITOR AND EPOTILONE DERIVATIVE | 2002 |
|
RU2313345C2 |
Authors
Dates
2019-02-19—Published
2014-12-03—Filed